TE TECH Bio-Techne Загрузка... : Бычьи и медвежьи мнения аналитиков

Lower rate volatility boosts US growth equities.

AI remains the dominant secular market theme.

Rotate from overbought tech into financials.

Premarket movers report shows semiconductor stocks surging while hyperscalers decline.

Merck KGaA agrees to acquire Bio-Techne Corporation for 11.3 billion dollars in its largest.

Merck agrees to acquire Bio-Techne for 73 dollars per share in an all-cash deal.

Activist investor Ananym Capital Management has built a stake in Bio-Techne and is pushing.

Guidance is cautious, projecting flat to low single-digit growth in the near term due to lingering biotech softness, but management points to a stronger FY2027 as funding translates to spending and company-specific headwinds roll off.

Tech to lead market gains.

Reduce exposure to overowned tech stocks.

The market summary states the Nasdaq 100 was higher by about 1.2% as people were "taking a bid back into tech companies" on optimism about a potential end to the Iran conflict. A de-escalation in Iran reduces geopolitical risk premiums, favoring growth-oriented sectors like technology. The sector was a highlighted leader in the day's rally. The explicit mention of capital flowing back into tech as a direct response to positive geopolitical developments indicates a clear, positive short-term catalyst for the sector. The Iran conflict does not de-escalate as expected, or other macro headwinds re-emerge.

The Nasdaq 100 is in a correction, down over 10% from its peak. Tech is getting hit from macro pressures (higher yields, oil) and sector-specific AI disruption fears. Higher oil and rates compound to create a multiple compression environment for growth stocks. The sector is also facing idiosyncratic disruption scares (e.g., AI in cybersecurity, memory chips). In the near term, tech is not a safe haven and is exposed to both macro and micro headwinds. A rapid de-escalation in Iran could bring down oil and yields, relieving the macro pressure. Strong earnings revisions could also provide support.

Management is confident in a gradual recovery, supported by easing headwinds and improvement in end markets.

Management guidance is mixed: Q2 organic growth is expected to be flat (consistent with Q1), with a return to positive organic growth expected only in the second half of the year as they lap prior-year headwinds.